๐จ BREAKING Scientists may have just cracked the code on Alzheimer's and Parkinson's โ WITH ONE PILL.
A drug called Buntanetap was just published in a peer-reviewed journal with Phase 3 data.
Phase 3 means that we are on the verge of FDA approval.
It targets the ROOT CAUSE of both diseases simultaneously.
Here's what you need to know ๐งต๐
#Alzheimers #Parkinsons
VIDEO
Tweet 2
Most people think Alzheimer's and Parkinson's are totally separate diseases.
They're not.
At autopsy, ~1 in 3 Alzheimer's patients have Lewy body (Parkinson's-type) protein in their brain.
And ~50% of Lewy body dementia patients have full Alzheimer's pathology too.
Same brain. Multiple diseases. Quietly overlapping. ๐ง
That's called co-pathology โ and it's why targeting just one protein may never be enough. ๐
#Dementia #Neurodegeneration
Most people think Alzheimer's and Parkinson's are totally separate diseases.
They're not.
At autopsy, ~1 in 3 Alzheimer's patients have Lewy body (Parkinson's-type) protein in their brain.
And ~50% of Lewy body dementia patients have full Alzheimer's pathology too.
Same brain. Multiple diseases. Quietly overlapping. ๐ง
That's called co-pathology โ and it's why targeting just one protein may never be enough. ๐
#Dementia #Neurodegeneration
There are FOUR driving neurodegeneration:
๐ด Amyloid-ฮฒ
๐ Tau
๐ก Alpha-Synuclein
๐ข TDP-43
Every approved drug targets just one of these.
Buntanetap targets all four โ simultaneously.
That's not an upgrade. That's a completely different philosophy. ๐
#Alzheimers #Buntanetap
๐ด Amyloid-ฮฒ
๐ Tau
๐ก Alpha-Synuclein
๐ข TDP-43
Every approved drug targets just one of these.
Buntanetap targets all four โ simultaneously.
That's not an upgrade. That's a completely different philosophy. ๐
#Alzheimers #Buntanetap
How does it work?
Buntanetap doesn't clean up protein AFTER it's already damaged your brain.
It stops the proteins from being MADE in the first place.
It binds to mRNA โ the blueprint โ before toxic proteins are assembled.
Think of it as cutting the factory order, not cleaning up the mess. ๐ญ
#Parkinsons #Neurodegeneration
Buntanetap doesn't clean up protein AFTER it's already damaged your brain.
It stops the proteins from being MADE in the first place.
It binds to mRNA โ the blueprint โ before toxic proteins are assembled.
Think of it as cutting the factory order, not cleaning up the mess. ๐ญ
#Parkinsons #Neurodegeneration
VIDEO
The clinical trial results are IN.
๐ Phase 2/3 Study:
โข 351 patients
โข 54 sites across the US
โข 3 doses tested
โข 12 weeks
Result: Statistically significant improvement in COGNITION in early Alzheimer's patients.
The 30mg dose showed +3.3 points on the ADAS-Cog11 scale vs placebo.
P < 0.001. ๐ฌ
#Alzheimers #ClinicalTrials
๐ Phase 2/3 Study:
โข 351 patients
โข 54 sites across the US
โข 3 doses tested
โข 12 weeks
Result: Statistically significant improvement in COGNITION in early Alzheimer's patients.
The 30mg dose showed +3.3 points on the ADAS-Cog11 scale vs placebo.
P < 0.001. ๐ฌ
#Alzheimers #ClinicalTrials
VIDEO
But cognition is just one piece.
The biomarker data is where it gets REALLY interesting.
After treatment, researchers measured:
๐ Tau โ REDUCED
๐ TDP-43 โ REDUCED
๐ Neurofilament Light (NfL) โ REDUCED
๐ Neuroinflammation markers (IL-6, IFN-ฮณ) โ REDUCED
This isn't just symptom relief.
This is hitting the BIOLOGY.
#Buntanetap #BrainHealth
The biomarker data is where it gets REALLY interesting.
After treatment, researchers measured:
๐ Tau โ REDUCED
๐ TDP-43 โ REDUCED
๐ Neurofilament Light (NfL) โ REDUCED
๐ Neuroinflammation markers (IL-6, IFN-ฮณ) โ REDUCED
This isn't just symptom relief.
This is hitting the BIOLOGY.
#Buntanetap #BrainHealth
Now for Parkinson's.
Buntanetap also completed a Phase 3 PD trial.
523 patients.
6 months.
Patients diagnosed 3+ years:
โ Statistically significant motor improvements
โ Cognitive decline HALTED overall
โ Plasma tau REDUCED
Alpha-synuclein is the main villain in Parkinson's.
Buntanetap targets it too.
This is rare. ๐ง
#Parkinsons #ClinicalTrials
Buntanetap also completed a Phase 3 PD trial.
523 patients.
6 months.
Patients diagnosed 3+ years:
โ Statistically significant motor improvements
โ Cognitive decline HALTED overall
โ Plasma tau REDUCED
Alpha-synuclein is the main villain in Parkinson's.
Buntanetap targets it too.
This is rare. ๐ง
#Parkinsons #ClinicalTrials
What about safety? This is where Big Pharma drugs often fail.
Buntanetap:
โ Well tolerated at ALL doses
โ Safe in ApoE4 gene carriers (highest AD risk group)
โ No major drug-related serious events
โ Compatible with existing AD medications
And it's a PILL.
Not an IV infusion every two weeks.
That alone is a massive advantage. ๐
#Alzheimers #Parkinsons
Buntanetap:
โ Well tolerated at ALL doses
โ Safe in ApoE4 gene carriers (highest AD risk group)
โ No major drug-related serious events
โ Compatible with existing AD medications
And it's a PILL.
Not an IV infusion every two weeks.
That alone is a massive advantage. ๐
#Alzheimers #Parkinsons
The FDA is paying attention.
In October 2024: FDA cleared Annovis to proceed with Phase 3 trials in Alzheimer's.
In February 2026: An independent safety board (DSMB) reviewed the ongoing Phase 3 and said:
"No safety concerns. Continue as planned."
This is a green light from independent watchdogs. ๐ฆ
#Buntanetap #Alzheimers
In October 2024: FDA cleared Annovis to proceed with Phase 3 trials in Alzheimer's.
In February 2026: An independent safety board (DSMB) reviewed the ongoing Phase 3 and said:
"No safety concerns. Continue as planned."
This is a green light from independent watchdogs. ๐ฆ
#Buntanetap #Alzheimers
The pivotal Phase 3 is happening RIGHT NOW.
๐ 760 patients
๐ 83 locations across the US
๐ Only biomarker-confirmed early AD (pTau217+)
๐ 18-month trial โ symptomatic + disease-modifying readouts
โฑ๏ธ First results expected: Late 2026 / Early 2027
โฑ๏ธ Full disease-modification data: 2027โ2028
This is the make-or-break moment. ๐ฏ
#Buntanetap #Alzheimers
๐ 760 patients
๐ 83 locations across the US
๐ Only biomarker-confirmed early AD (pTau217+)
๐ 18-month trial โ symptomatic + disease-modifying readouts
โฑ๏ธ First results expected: Late 2026 / Early 2027
โฑ๏ธ Full disease-modification data: 2027โ2028
This is the make-or-break moment. ๐ฏ
#Buntanetap #Alzheimers
The pivotal Phase 3 is happening RIGHT NOW.
๐ 760 patients
๐ 83 locations across the US
๐ Only biomarker-confirmed early AD (pTau217+)
๐ 18-month trial โ symptomatic + disease-modifying readouts
โฑ๏ธ First results expected: Late 2026 / Early 2027
โฑ๏ธ Full disease-modification data: 2027โ2028
This is the make-or-break moment. ๐ฏ
#Buntanetap #Alzheimers
๐ 760 patients
๐ 83 locations across the US
๐ Only biomarker-confirmed early AD (pTau217+)
๐ 18-month trial โ symptomatic + disease-modifying readouts
โฑ๏ธ First results expected: Late 2026 / Early 2027
โฑ๏ธ Full disease-modification data: 2027โ2028
This is the make-or-break moment. ๐ฏ
#Buntanetap #Alzheimers
Compare this to approved Alzheimer's drugs.
Lecanemab & Donanemab (currently approved):
โ IV infusion every 2 weeks
โ Brain swelling risk (ARIA)
โ Only targets amyloid
โ ~$26,500/year
Buntanetap (if approved):
โ Once-daily pill
โ Targets 4 proteins
โ No IV
โ Potentially far cheaper
This is why researchers are excited.
#Buntanetap #Neurodegeneration
Lecanemab & Donanemab (currently approved):
โ IV infusion every 2 weeks
โ Brain swelling risk (ARIA)
โ Only targets amyloid
โ ~$26,500/year
Buntanetap (if approved):
โ Once-daily pill
โ Targets 4 proteins
โ No IV
โ Potentially far cheaper
This is why researchers are excited.
#Buntanetap #Neurodegeneration
Important caveats โ I won't hide them.
โ ๏ธ The PD Phase 3 missed its primary endpoint overall (benefit was in subgroups only)
โ ๏ธ The AD Phase 2/3 was only 12 weeks
โ ๏ธ Disease modification is NOT YET proven โ Phase 3 is the real test
โ ๏ธ No FDA approval yet
The science is promising.
But Phase 3 data (2026-2028) decides everything.
This is not a guaranteed win. Stay skeptical AND curious.
#Buntanetap #ClinicalTrials
โ ๏ธ The PD Phase 3 missed its primary endpoint overall (benefit was in subgroups only)
โ ๏ธ The AD Phase 2/3 was only 12 weeks
โ ๏ธ Disease modification is NOT YET proven โ Phase 3 is the real test
โ ๏ธ No FDA approval yet
The science is promising.
But Phase 3 data (2026-2028) decides everything.
This is not a guaranteed win. Stay skeptical AND curious.
#Buntanetap #ClinicalTrials
So here's the bottom line:
Buntanetap is:
โ Oral, once daily
โ Published in peer-reviewed journals (Nature, 2026)
โ Phase 3 safety cleared
โ Targeting 4 proteins no other approved drug touches simultaneously
The pivotal results come in 2026โ2028.
If it works, this changes everything.
Follow for updates.
Share if someone you love has AD or PD. ๐ง โค๏ธ
[Full source list in reply ๐]
#Alzheimers #Parkinsons #Buntanetap
Buntanetap is:
โ Oral, once daily
โ Published in peer-reviewed journals (Nature, 2026)
โ Phase 3 safety cleared
โ Targeting 4 proteins no other approved drug touches simultaneously
The pivotal results come in 2026โ2028.
If it works, this changes everything.
Follow for updates.
Share if someone you love has AD or PD. ๐ง โค๏ธ
[Full source list in reply ๐]
#Alzheimers #Parkinsons #Buntanetap
Buntanetap is exciting because it targets multiple overlapping proteins that drive most cases.
I wrote about this bigger shift ... Parkinsonโs as many different diseases here.
Copathology needs to be addressed.
neuroscope.substack.com/p/a-new-era-foโฆ
I wrote about this bigger shift ... Parkinsonโs as many different diseases here.
Copathology needs to be addressed.
neuroscope.substack.com/p/a-new-era-foโฆ
Generated by Thread Navigator
Press โ + S to quick-export